443 related articles for article (PubMed ID: 19789122)
1. [Erythropoietin: indications and measurement].
Klein E; Georges A; Brossaud J; Bosredon Kd; Bordenave L; Corcuff JB
Ann Biol Clin (Paris); 2009; 67(5):505-15. PubMed ID: 19789122
[TBL] [Abstract][Full Text] [Related]
2. [Erythropoietin determination in clinical medicine].
Urabe A
Rinsho Byori; 1993 Apr; 41(4):361-5. PubMed ID: 8350498
[TBL] [Abstract][Full Text] [Related]
3. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
4. [Physiology of eryhtropoietin and its therapeutic use].
Casadevall N
Ann Pharm Fr; 1996; 54(4):151-6. PubMed ID: 8881101
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin-- measurement and clinical applications.
Marsden JT
Ann Clin Biochem; 2006 Mar; 43(Pt 2):97-104. PubMed ID: 16536911
[TBL] [Abstract][Full Text] [Related]
6. "Benign erythrocytosis" and other familial and congenital polycythemias.
Prchal JT; Sokol L
Eur J Haematol; 1996 Oct; 57(4):263-8. PubMed ID: 8982288
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia and oxygen sensing.
Maran J; Prchal J
Pathol Biol (Paris); 2004 Jun; 52(5):280-4. PubMed ID: 15217714
[TBL] [Abstract][Full Text] [Related]
8. [Erythropoietin and radiotherapy].
Le Fur E; Albarghach MN; Pradier O
Cancer Radiother; 2010 Jan; 14(1):81-6. PubMed ID: 20018547
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin: mechanisms of action and indications for treatment.
Vreugdenhil G; Frenken LA; Koene RA
Neth J Med; 1993 Jun; 42(5-6):187-202. PubMed ID: 8377877
[TBL] [Abstract][Full Text] [Related]
10. Beyond anemia: the clinical impact of the physiologic effects of erythropoietin.
Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
Semin Dial; 2008; 21(5):447-54. PubMed ID: 18573136
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin therapy: need for rationality and active surveillance.
Cazzola M
Haematologica; 2003 Jun; 88(6):601-5. PubMed ID: 12801832
[No Abstract] [Full Text] [Related]
12. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse.
Abellan R; Ventura R; Pichini S; Palmi I; Bellver M; Olive R; Pacifici R; Pascual JA; Zuccaro P; Segura J
Int J Sports Med; 2007 Jan; 28(1):9-15. PubMed ID: 16804802
[TBL] [Abstract][Full Text] [Related]
13. [Secondary polycythemias: the role of erythropoietin].
Rognon R; Piguet D; Mégevand M; Kaeser P
Rev Med Suisse Romande; 1993 Nov; 113(11):865-71. PubMed ID: 8272712
[TBL] [Abstract][Full Text] [Related]
14. Serum erythropoietin titers in hematological malignancies and related diseases.
Urabe A; Mitani K; Yoshinaga K; Iki S; Yagisawa M; Ohbayashi Y; Takaku F
Int J Cell Cloning; 1992 Nov; 10(6):333-7. PubMed ID: 1460322
[TBL] [Abstract][Full Text] [Related]
15. To give or not to give recombinant EPO to anemia endangered cancer patients.
Sulkowska M; Wincewicz A; Chabowska A; Kanczuga-Koda L; Szymanska M; Koda M; Witkowska E; Sulkowski S
Prague Med Rep; 2006; 107(3):281-9. PubMed ID: 17385400
[TBL] [Abstract][Full Text] [Related]
16. EPO's alter ego: erythropoietin has multiple actions.
Lappin TR; Maxwell AP; Johnston PG
Stem Cells; 2002; 20(6):485-92. PubMed ID: 12456956
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin-dependent anaemia: a possible complication of diabetic neuropathy.
Hadjadj S; Torremocha F; Fanelli A; Brizard A; Bauwens M; Maréchaud R
Diabetes Metab; 2001 Jun; 27(3):383-5. PubMed ID: 11431605
[TBL] [Abstract][Full Text] [Related]
18. The potential of erythropoietin and related strategies to stimulate erythropoiesis.
Eckardt KU
Curr Opin Investig Drugs; 2001 Aug; 2(8):1081-5. PubMed ID: 11892917
[TBL] [Abstract][Full Text] [Related]
19. Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting.
Pradella M; Cavill I; d'Onofrio G
Clin Lab Haematol; 1996 Dec; 18 Suppl 1():35-7. PubMed ID: 9054717
[TBL] [Abstract][Full Text] [Related]
20. [The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, and hypertension: beyond anaemia].
Ortega LM; Contreras G
Nefrologia; 2009; 29(4):288-94. PubMed ID: 19668298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
